New York State Common Retirement Fund Purchases 31,231 Shares of Replimune Group, Inc. (NASDAQ:REPL)

New York State Common Retirement Fund raised its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 260.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,204 shares of the company’s stock after purchasing an additional 31,231 shares during the quarter. New York State Common Retirement Fund owned 0.06% of Replimune Group worth $523,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in REPL. Charles Schwab Investment Management Inc. increased its stake in Replimune Group by 12.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after acquiring an additional 52,498 shares during the last quarter. Geode Capital Management LLC raised its holdings in Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the period. Barclays PLC raised its holdings in Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after buying an additional 98,791 shares during the period. LMR Partners LLP lifted its position in Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after buying an additional 48,920 shares during the last quarter. Finally, State Street Corp increased its position in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Stock Down 0.8 %

NASDAQ:REPL opened at $12.02 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a market cap of $925.72 million, a PE ratio of -3.92 and a beta of 1.30. The company has a 50-day moving average of $12.78 and a 200 day moving average of $12.03. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on REPL. BMO Capital Markets lifted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Jefferies Financial Group raised their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Replimune Group presently has a consensus rating of “Buy” and a consensus price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.